Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and/or anthracyclines.  Journal of Cancer Survivorship.  15:738-747. 2021
2021 Risk, Racial Disparity, and Outcomes among Patients with Cancer and COVID-19 Infection.  JAMA Oncology.  7:1064-1065. 2021
2021 Expenditures among young adults with acute lymphoblastic leukemia by site of care.  Cancer.  127:1901-1911. 2021
2021 Poverty and Survival in Childhood Cancer: A Framework to Move Toward Systemic Change 2021
2020 Isolation of DNA-free RNA from human bone marrow mononuclear cells: Comparison of laboratory methods 2020
2019 Lung cancer in nonelderly patients: Facility and patient characteristics associated with not receiving treatment 2019
2018 Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: Across oncology services and regardless of clinical trial enrollment.  Cancer Epidemiology, Biomarkers and Prevention.  27:1133-1141. 2018
2017 T-cell prolymphocytic leukemia in an adolescent with ataxiatelangiectasia: Novel approach with a JAK3 inhibitor (tofacitinib).  Blood Advances.  1:2724-2728. 2017
2017 Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.  Leukemia.  31:1450-1453. 2017
2017 Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: Impact of care at specialized cancer centers on survival outcome.  Cancer Epidemiology, Biomarkers and Prevention.  26:312-320. 2017
2016 Value, access, and cost of cancer care delivery at academic cancer centers 2016
2015 Impact of tailored education on awareness of personal risk for therapy-related complications among childhood cancer survivors.  Journal of Clinical Oncology.  33:3887-3893. 2015
2015 Impact of care at comprehensive cancer centers on outcome: Results from a population-based study.  Cancer.  121:3885-3893. 2015
2015 Long-term pulmonary function in survivors of childhood cancer.  Journal of Clinical Oncology.  33:1592-1600. 2015
2015 Piecing together the puzzle of disparities in adolescents and young adults.  Cancer.  121:1168-1171. 2015
2014 Impact of care at NCI Comprehensive Cancer Centers (NCICCC) on cancer outcome: Results from a population-based study..  Journal of Clinical Oncology.  32:188. 2014
2014 Impact of treatment site in adolescents and young adults with central nervous system tumors 2014
2013 Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens..  British Journal of Haematology.  162:376-382. 2013

Chapter

Year Title Altmetric
2017 Making Ends Meet: Financial Issues from the Perspectives of Patients and Their Health-Care Team.  667-685. 2017

Principal Investigator On

Investigator On

  • A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia, Study ITCC-054/COG AAML1921  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ALTE1631, A Randomized Web-Based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Developing a Network to Utilize Administrative and Clinical Data for Childhood, Adolescent and Young Adult Oncology Survivorship Research  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Hyundai Hope on Wheels Impact Grant  awarded by HYUNDAI HOPE ON WHEELS
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • L-12610 Entitled: Pilot Study Using Induction Chemo-Immunotherapy Followed by Consolidation with Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults  awarded by NEW YORK MEDICAL COLLEGE
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma  awarded by NEW YORK MEDICAL COLLEGE
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)

    • Education And Training

  • MassGeneral Hospital for Children, Internship
  • Masachusetts General Hospital, Residency
  • Children's Hospital Los Angeles, Postdoctoral Fellowship
  • Doctor of Medicine, University of Florida 2002

    • Full Name

  • Julie Wolfson-Stockman